Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
04 March 1999Website:
http://www.aethlonmedical.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:59:22 GMTDividend
Analysts recommendations
Institutional Ownership
AEMD Latest News
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments.
SAN DIEGO , June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06200Treatments-for-Cancer-Patients-with-Solid-Tumors.asp Research released this year predicts, "The solid tumor therapeutics market size will grow from USD 222.71 Billion in 2023 to USD 885.44 Billion in 10 years.
Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , June 18, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on June, 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for three years, until June 13, 2027.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06070Virus-Treatments-Post-Covid-19.asp The threat of viruses is back in the news with multiple news sources, including the Guardian reporting, "The World Health Organization (WHO) has said a man's death in Mexico was caused by a strain of bird flu called H5N2 that has never before been found in a human.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06030Blood-Purification-Medical-Devices.asp According to Straits Research, "The global blood purification equipment market size was valued at USD 17,755.6 million in 2021.
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO , June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. "We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical.
Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR Jim Frakes - Interim CEO and CFO Steven LaRosa - CMO Guy Cipriani - COO Conference Call Participants Marla Marin - Zacks Thomas McGovern - Maxim Group Vernon Bernardino - H.C. Wainwright Operator Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call.
What type of business is Aethlon Medical?
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
What sector is Aethlon Medical in?
Aethlon Medical is in the Healthcare sector
What industry is Aethlon Medical in?
Aethlon Medical is in the Medical Devices industry
What country is Aethlon Medical from?
Aethlon Medical is headquartered in United States
When did Aethlon Medical go public?
Aethlon Medical initial public offering (IPO) was on 04 March 1999
What is Aethlon Medical website?
https://www.aethlonmedical.com
Is Aethlon Medical in the S&P 500?
No, Aethlon Medical is not included in the S&P 500 index
Is Aethlon Medical in the NASDAQ 100?
No, Aethlon Medical is not included in the NASDAQ 100 index
Is Aethlon Medical in the Dow Jones?
No, Aethlon Medical is not included in the Dow Jones index
When does Aethlon Medical report earnings?
Next earnings report date is not announced yet